MedCity News | July 26, 2018 — Company raising $50 million Series C round and in early stages of securing reimbursement for test. By ALARIC DEARMENT Sunnyvale, California-based CellMax Life said Tuesday it was granted the patents for its CMx biomimetic platform, which is designed to detect circulating tumor cells (CTCs) in the blood. It is...

Patents cover entirety of sub-$200 test and platform, which isolates rare circulating tumor cells (CTCs) from one tube of blood CellMax Life, enabling early cancer detection and management with affordable, non-invasive blood tests, announced today that six U.S. patents have been granted for its biomimetic platform CMx, which detects circulating tum...

Chicago Tribune | June 27, 2018 — Medical tests save lives. Discovering diseases before they become more serious can mean the difference between life and death. But many Americans say they don’t have time to see a doctor, live too far from a medical facility or are so uncomfortable with examinations that they avoid tests altogether....

Scientific American | June 20, 2018 — Colorectal Cancer Is on the Rise in Young Adults They’re reluctant to have invasive colonoscopies, but a simple blood test could improve compliance By Shai Friedland There has been increasing attention directed towards the rising rate of colorectal cancer in younger age groups. In the United States, there...

MedTech Breakthrough Awards, 2018 — Leading Cancer Management Company Wins Prestigious Award for its Proprietary Circulating Tumor Cell (CTC) CMx Platform CellMax Life, a leading cancer detection and management company with clinically proven, affordable and non-invasive early cancer detection blood tests, announced today that its proprietary ...

Becker’s GI & Endoscopy | May 30, 2018  Cancer diagnostics company CellMaxLife launched Zenith, the U.S. trial of its circulating tumor cell blood test to detect colorectal cancer. Here are four things to know: 1. Patients coming in for routine colorectal cancer screening through colonoscopy or stool tests will be offered CellMaxLife̵...

ASCO Reading Room 05.31.2018 — A new blood test appears to detect expression of the programmed death-ligand 1 (PD-L1) protein in circulating tumor cells (CTCs) with high sensitivity, enabling repeat testing to monitor a patient’s response to immunotherapy throughout the course of treatment. The test is able to capture CTCs for PD-L1 testing i...

NEW YORK (360Dx) – CellMax Life announced this week that it is beginning a new clinical trial, which will further validate its circulating tumor cell (CTC) colorectal cancer screening test in American subjects, with the goal of supporting a submission for approval by the US Food and Drug Administration. The study is being conducted with...

  SUNNYVALE, Calif., May 30, 2018 /PRNewswire/ — CellMax Life, a leading cancer diagnostics company enabling early cancer detection with affordable non-invasive blood tests, today announced it is commencing Zenith, a U.S. clinical study for its circulating tumor cell (CTC) blood test, which can transform the way colorectal cancer is dete...

May 2018 | Laboratory Economics CellMax Life (Sunnyvale, CA) has already been marketing its blood test for the early detection of colon cancer in Asia for the past two years and plans to o er it in the U.S. market as a laboratory-developed test within the next few months, according to CEO Atul Sharan. Download the...

Apr 10, 2018 | NEW YORK (GenomeWeb) CellMax Life and IncellDx said today that they have signed an agreement to jointly develop and market circulating tumor cell tests across multiple solid tumors and indications, including personalized therapy selection and monitoring. Under the agreement, CellMax will combine its technology for CTC isolation with ...

SUNNYVALE, CALIF. (PRWEB) MARCH 28, 2018 CellMax Life, a leading cancer diagnostics company enabling early cancer detection with affordable non-invasive blood tests, announced today the U.S. launch of a blood test to detect the expression of PD-L1 – a key protein involved in suppressing the immune system – in circulating tumor cells (CTCs). Since i...

Wall Street Journal, March 16, 2018 7:30 a.m. ET Theranos Inc.’s fall underscores the need for medical startups to be transparent in their dealings with investors and to publish data supporting their technology to gain credibility, venture capitalists and entrepreneurs said. Theranos, formed in 2003, climbed to a valuation of more than $9 billion, ...

This study showed that the CellMax CTC blood test can predict which patients in the gray zone will need/have a positive prostate biopsy with a much lower false positive rate than current standard of care tests, potentially reducing unnecessary biopsies in this group by up to 90 percent....

A new, noninvasive blood test can reliably detect prostate cancer in patients with inconclusive PSA tests, the test’s developer, CellMax Life, recently announced. Researchers say the company’s circulating tumor cell (CTC) blood test could reduce the number of unnecessary biopsies by up to 90 percent....

Wall Street Journal highlights CellMax Life’s circulating tumor cell (CTC) as a proven blood testing platform to detect cancer early…. beyond standard DNA sequencing on the Illumina platform. ...

THURSDAY, Jan. 18, 2018 (U.S. News & World Report/HealthDay News) A simple, cheap blood test to detect colon cancer — even in its early stages — appears highly effective and accurate, new research indicates. The test detects so-called “circulating tumor cells” (CTCs). Researchers tested it on 620 people in Taiwan who wer...

THURSDAY, Jan. 18, 2018, 11:06 P.M. E.S.T. (New York Times/The Associated Press) Scientists are reporting progress on a blood test to detect many types of cancer at an early stage, including some of the most deadly ones that lack screening tools now. Many groups are working on liquid biopsy tests, which look for DNA and...

New test could potentially be offered at less than $150 enabling high compliance and global adoption SUNNYVALE, Calif., Jan. 17, 2018 /PRNewswire/ — CellMax Life, a leading cancer diagnostics company enabling early cancer detection and management with globally affordable non-invasive blood tests, today announced results from a new study showi...

...

...

...

...

...

...

...

...

...